Your Directors have pleasure in presenting the 53rd Annual Report and Audited Senior Joint Commissioner,. Kolkata. Delhi Value Added Tax. Ranbaxy Laboratories Limited Annual Report CHAIRMAN’S MESSAGE Down Inc. Germany (upto 16 December ) 11 Ranbaxy Unichem Co. Get Ranbaxy Laboratories latest Balance Sheet, Financial Statements and Ranbaxy Laboratories detailed profit and loss accounts.

Author: Gukinos Zolotaxe
Country: Samoa
Language: English (Spanish)
Genre: Health and Food
Published (Last): 12 October 2016
Pages: 59
PDF File Size: 17.68 Mb
ePub File Size: 19.53 Mb
ISBN: 685-7-14770-623-1
Downloads: 61181
Price: Free* [*Free Regsitration Required]
Uploader: Salkree

The sales consideration of Rs.

Annual Reports & Presentations | Sun Pharmaceutical Industries Ltd.

If the shares are listed on more than one stock exchange, then the stock exchange where there is highest trading volume on the said date shall be considered. The Company received the fnal assessment order from the AO in November whereby demand of Rs Quick Links for ranbaxylaboratories.


Daiichi Sankyo Propharma Co. You will be able to download it at any time during the subscription period. These derivatives are not used for trading or speculation purposes. The same is expected to be resumed shortly. Options lapse, if they are not exercised prior to the expiry date, which is three months from the date of the vesting. Ranbaxy Laboratories is not traded in the last 30 days.

The Company has also issued redeemable non-convertible debentures which are listed for trading on the NSE in India. Consequent to the fndings of the above exercise, the carrying amount of inventory has been written down by Rs. Hence, the Company has become a potentially sick company in terms of the provisions of Sick Industrial Companies Special Provisions Act, and requisite compliances under this Act would be made by the Company.


In calculating these provisions, the management has used the best information and estimates, presently available. The options vests evenly over a period of three repot from the date of grant. ESOP – provides that the grant price will be the face value of the equity share. Clicking on the download link will add the report to your downloaded reports.

As per the Scheme, the share exchange ratio has been proposed as 0. The amount above represents the difference payable.

Ranbaxy Laboratories

Nifty bounces over ; Bharti languishes 17 Feb 10 Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol. Free reports will not be deducted from your subscription. Segment information In accordance with AS 17, Segment Reporting, segment information has been given in the consolidated fnancial statements of the Company, and therefore, no separate disclosure on segment information is given in these fnancial statements.

The Company expects to resume the operations shortly. The Company is fully cooperating with this information request and is in dialogue with the US DOJ for submission of the requisite information. Since ranbax matter involves signifcant judgement and in view of the inherent uncertainty of the present situation, the actual amounts may differ eventually.


Thank you for your kind understanding. Key markets of US, Europe not so promising 27 Oct 09 Contingent liabilities and commitments to the extent not provided for As at As o 31 March 31 December Contingent liabilities i Guarantees a Letter of comfort on behalf of subsidiaries, to the extent of limits 6, It also includes a demand of Rs.

Company overview Ranbaxy Laboratories Limited ”the Company” together with its subsidiaries and associates, operates as an integrated international pharmaceutical organisation with businesses encompassing the entire value chain in the marketing, production and distribution of pharmaceutical products. Click here to change registered Email ID. Foreign funds hint at hiking India allocation 25 Mar annkal Pursuant to the transaction, the Company has recorded a gain of Rs.

Commitments i Estimated amount of contracts remaining to be executed on capital account and not The Company has not accepted the same and has fled its objections before the DRP.

Dion Global Solutions Limited.

ESOS provides that the grant price of options will be the latest available closing price on the stock exchange on which the shares of the Company are listed, prior to the date of the meeting of the Committee in which the options are granted.